Lineage Cell Therapeutics (LCTX) Capital Expenditures (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Capital Expenditures came in at $55000.0 in Q1 2026, down 43.3% year-on-year from $97000.0 in Q1 2025, and down 88.93% quarter-over-quarter from $497000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Capital Expenditures (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $55000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures fell 43.3% year-over-year to $55000.0 in Q1 2026; TTM through Mar 2026 was $480000.0, a 23.08% decrease from a year earlier, with the FY2025 full-year figure at $522000.0, down 7.61% from the prior year.
- Capital Expenditures fell to $55000.0 in Q1 2026 per LCTX's latest filing, from $497000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $554000.0 in Q4 2024 and bottomed at -$401000.0 in Q4 2022.
- The 5-year median for Capital Expenditures is $91000.0 (2023), against an average of $108470.6.
- Across the five-year window, Capital Expenditures plunged 374.66% in 2022 and soared 508.79% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at -$401000.0 in 2022, then jumped by 122.69% to $91000.0 in 2023, then surged by 508.79% to $554000.0 in 2024, then fell by 10.29% to $497000.0 in 2025, then plunged by 88.93% to $55000.0 in 2026.
- Per Business Quant, the three latest LCTX Capital Expenditures figures stand at $55000.0 (Q1 2026), $497000.0 (Q4 2025), and -$86000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | 55,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55,000.00 |
| Mar 31, 2026 | 55,000.00 |
| Dec 31, 2025 | 497,000.00 |
| Dec 31, 2025 | 497,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 97,000.00 |
| Mar 31, 2025 | 97,000.00 |
| Dec 31, 2024 | 554,000.00 |
| Dec 31, 2024 | 554,000.00 |
| Sep 30, 2024 | -77,000.00 |
| Sep 30, 2024 | -77,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | 91,000.00 |
| Dec 31, 2023 | 91,000.00 |